HomeGYRE • NASDAQ
Gyre Therapeutics Inc
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 22.06M | -18.82% |
Operating expense | 18.89M | 4.24% |
Net income | 2.70M | -64.18% |
Net profit margin | 12.23 | -55.88% |
Earnings per share | — | — |
EBITDA | 2.81M | -66.91% |
Effective tax rate | 19.44% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 29.89M | -19.97% |
Total assets | 129.79M | 6.38% |
Total liabilities | 25.49M | -23.32% |
Total equity | 104.30M | — |
Shares outstanding | 88.10M | — |
Price to book | 14.62 | — |
Return on assets | 4.45% | — |
Return on capital | 5.52% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | 2.70M | -64.18% |
Cash from operations | -129.00K | -104.47% |
Cash from investing | 1.97M | 127.24% |
Cash from financing | 1.34M | 104.26% |
Net change in cash | 3.23M | 186.79% |
Free cash flow | 582.63K | -81.38% |
Previous close
$11.40
Day range
$10.23 - $11.50
Year range
$6.11 - $18.94
Market cap
972.27M USD
Avg Volume
119.57K
P/E ratio
143.43
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
1997
Headquarters
Website
Employees
579
